Cervical Cancer trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Cervical Cancer. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month4 studies across 4 companies, in the next 180 days.
August 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| NRIX | Nurix Therapeutics, Inc. | A Study of NX-1607 in Adults With Advanced MalignanciesNCT05107674Incidence of treatment-emergent adverse events (TEAEs), including Grade ≥ 3 TEAEs, treatment-emergent serious adverse events (SAEs), TEAEs leading to study drug discontinuation, and deaths due to TEAEs | Phase 1 | Recruiting | 2026-08-31 | in 11 d | 2025-09-09 |
| RADX | Radiopharm Theranostics, Ltd | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid TumorsNCT05799274Radiation dosimetry of RAD301 | Phase 1 | Recruiting | Aug 2026 | ≤ 11 d | 2026-07-17 |
November 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PGEN | Precigen, Inc | PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical CancerNCT06157151Determine the Objective Response Rate (ORR) following treatment with PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer. | Phase 2 | Recruiting | 2026-11-11 | in 83 d | 2026-04-23 |
December 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| TCRX | TScan Therapeutics, Inc. | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid TumorsNCT05973487Evaluate the safety of monotherapy and T- Plex combination TCR-Ts | Phase 1 | Active, not recruiting | 2026-12-30 | in 132 d | 2025-11-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Cervical Cancer
most recently updated first79 studies match.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | — | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesNCT04644068The number of subjects with adverse events/serious adverse events | Phase 1/2 | Active, not recruiting | Drug: AZD5305, Paclitaxel, Carboplatin, T- Dxd, Dato-DXd, Camizestrant | Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5 | 702 | 2020-11-12 | 2027-05-28 | in 281 d | 2026-08-19 |
| BOLD | Boundless Bio, Inc. | $65M | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene AmplificationsNCT05827614Frequency and severity of treatment emergent adverse events (TEAEs) of BBI-355 as a single agent and in combination with each of the following agents: erlotinib, futibatinib, or BBI-825 | Phase 1 | Terminatedsponsor's stated reason: Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safety signal. | Drug: BBI-355, Erlotinib, Futibatinib, BBI-825 | Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head and Neck (HNSCC), Cutaneous Squamous Cell Carcinoma (CSCC), Cervical Squamous Cell Carcinoma, ER+ Breast Cancer, Leiomyosarcoma (LMS), Undifferentiated Pleomorphic Sarcoma (UPS), Pancreatic Cancer Metastatic, Small Cell Lung Cancer | 85 | 2023-03-24 | 2026-03-17actual | — | 2026-08-19 |
| AZN | AstraZeneca | — | A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)NCT06943833Progression-free Survival at 24 months (PFS24) | Phase 2 | Active, not recruiting | Biological: Volrustomig | Locally Advanced Cervical Cancer | 37 | 2025-03-31 | 2028-03-13 | in 571 d | 2026-08-18 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsNCT04895709Incidence of adverse events (AEs) | Phase 1/2 | Recruiting | Drug: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig | Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms | 1,109 | 2021-05-27 | 2031-08-31 | in 1,837 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical CancerNCT06952660Type, incidence and severity of ocular adverse events (AEs) | Phase 4 | Recruiting | Drug: TIVDAK | Cervical Cancer | 100 | 2025-05-07 | 2028-12-13 | in 846 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | Tucatinib Continuation StudyNCT07768358To monitor the safety and tolerability of tucatinib | Phase 4 | Not yet recruiting | Drug: tucatinib | HER2-positive Breast Cancer, Cervical Cancer, Biliary Tract Neoplasms, Urothelial Cancer, Advanced Non-Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer | 175 | 2026-08-24 | 2032-03-13 | in 2,032 d | 2026-08-17 |
| NXTC | NextCure, Inc. | $30M | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid TumorsNCT05572684results2026-08-13Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 | Phase 1/2 | Terminatedsponsor's stated reason: Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial. | Drug: NC410, pembrolizumab | Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer | 97 | 2022-10-06 | 2025-04-30actual | — | 2026-08-13 |
| AGEN | Agenus Inc. | $339M | A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)NCT03495882results2026-08-11Phase 2: Objective Response Rate (ORR) - Independent Endpoint Review Committee (IERC) | Phase 1/2 | Completed | Drug: Zalifrelimab, Balstilimab | Cervical Cancer | 175 | 2017-12-18 | 2022-07-15actual | — | 2026-08-11 |
| MGNX | MacroGenics | $261M | A Study of MGC026 in Participants With Advanced Solid TumorsNCT06242470Number of participants with adverse events (AEs) and serious AEs (SAEs), AEs leading to dose delay, AEs leading to dose reduction, AEs leading to treatment discontinuations, AEs meeting criteria for dose limiting toxicity, and AEs of special interest. | Phase 1 | Recruiting | Biological: MGC026 Dose Escalation, MGC026 Dose for Expansion | Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC) | 250 | 2024-03-06 | May 2028 | ≤ 650 d | 2026-08-11 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsNCT06172478Number of Participants With Objective Response Rate Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort) | Phase 2 | Recruiting | Drug: HER3-DXd | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer | 740 | 2024-02-26 | 2027-09-01 | in 377 d | 2026-08-10 |
| STRO | Sutro Biopharma, Inc. | $365M | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic CancerNCT07227168Part 1A: Number of participants with Dose-limiting Toxicities (DLTs) | Phase 1 | Recruiting | Drug: STRO-004, Pembrolizumab | Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Cervical Cancer, Endometrial Cancer, Urothelial Cancer | 200 | 2025-11-07 | Dec 2027 | ≤ 498 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsNCT06465069Phase 1a: To determine the recommended phase 2 dose (RP2D) optimal dose(s) of LY4052031 | Phase 1 | Recruiting | Drug: LY4052031 | Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer | 420 | 2024-07-01 | May 2027 | ≤ 284 d | 2026-08-05 |
| IOVA | Iovance Biotherapeutics, Inc. | $3.2B | Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical CarcinomaNCT03108495results2026-07-31Cohort 1 and 2: Objective Response Rate | Phase 2 | Terminatedsponsor's stated reason: After reviewing available safety and efficacy data to date, Iovance concluded the study reached the required number of events for evaluation of study endpoints. | Biological: LN-145, LN-145 + pembrolizumab | Cervical Carcinoma | 210 | 2017-06-22 | 2025-08-22actual | — | 2026-07-31 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced CancersNCT05891171Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Active, not recruiting | Drug: AB598, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin | Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC) | 40 | 2023-10-13 | Sep 2027 | ≤ 406 d | 2026-07-30 |
| AZN | AstraZeneca | — | Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)NCT06079671Progression-free Survival (PFS) based on the investigator assessment in all randomized participants (FAS) | Phase 3 | Recruiting | Biological: Volrustomig · Other: Placebo | Locally Advanced Cervical Cancer | 800 | 2023-09-22 | 2027-11-26 | in 463 d | 2026-07-29 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical CancerNCT03786081Dose escalation: Dose Limiting Toxicities (DLTs) | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor has decided to stop the trial based on strategic decisions | Drug: Tisotumab Vedotin, Bevacizumab, Pembrolizumab, Carboplatin | Cervical Cancer | 214 | 2019-02-27 | 2026-03-19actual | — | 2026-07-22 |
| AZN | AstraZeneca | — | DESTINY-PANTUMOUR04NCT07124000observationalReal world response rate (rwRR) | — | Recruiting | Drug: Trastuzumab deruxtecan | Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer | 100 | 2025-09-18 | 2028-03-30 | in 588 d | 2026-07-22 |
| RADX | Radiopharm Theranostics, Ltd | — | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid TumorsNCT05799274Radiation dosimetry of RAD301 | Phase 1 | Recruiting | Drug: RAD301 ([68Ga]-RAD301) | Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma, Cervical Cancer, Endometrial Cancer, Ovarian Cancer | 9 | 2023-11-09 | Aug 2026 | ≤ 11 d | 2026-07-17 |
| NTHI | Neonc Technologies, Inc. | $143M | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNCT06047379Phase 1: safety and tolerability of increasing dose levels of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or patients with select solid tumors with uncontrolled metastases to the brain | Phase 1/2 | Recruiting | Drug: NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab | Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma | 134 | 2023-11-01 | 2027-02-28 | in 192 d | 2026-07-16 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of Sigvotatug Vedotin in Advanced Solid TumorsNCT04389632Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: sigvotatug vedotin, pembrolizumab, cisplatin, carboplatin | Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms | 1,006 | 2020-06-08 | 2027-06-16 | in 300 d | 2026-07-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4170156 in Participants With Selected Advanced Solid TumorsNCT06400472Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY4170156 | Phase 1 | Recruiting | Drug: LY4170156, bevacizumab, carboplatin, Itraconazole, pembrolizumab | Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm, Colorectal Neoplasms | 495 | 2024-05-20 | Feb 2027 | ≤ 192 d | 2026-06-18 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsNCT06238479Phase 1a: To determine the recommended dose of LY4101174 | Phase 1 | Active, not recruiting | Drug: LY4101174 | Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer | 490 | 2024-03-05 | Mar 2027 | ≤ 223 d | 2026-05-22 |
| PGEN | Precigen, Inc | $2.4B | PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical CancerNCT06157151Determine the Objective Response Rate (ORR) following treatment with PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer. | Phase 2 | Recruiting | Biological: PRGN-2009 plus Pembrolizumab | Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, Recurrent Cervical Carcinoma, Metastatic Cervical Cancer | 24 | 2025-11-11 | 2026-11-11 | in 83 d | 2026-04-23 |
| AZN | AstraZeneca | — | ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid TumorsNCT06973161observationalOverall Survival | — | Completed | — | Bladder Cancer, Biliary Tract Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Pancreatic Cancer, Colorectal Cancer, Lung Cancer, Other Tumors | 140 | 2025-06-10 | 2026-03-17actual | — | 2026-04-08 |
| AGEN | Agenus Inc. | $339M | RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical CancerNCT03894215Objective Response Rate | Phase 2 | Terminatedsponsor's stated reason: Sponsor strategic decision | Drug: AGEN2034, AGEN1884 | Cervical Cancer | 211 | 2019-06-01 | 2025-03-26actual | — | 2026-03-27 |
| RADX | Radiopharm Theranostics, Ltd | — | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsNCT07189871Recommended dose(s) of 177Lu-BetaBart for future exploration (phase 1) | Phase 1/2 | Recruiting | Drug: 177Lu-BetaBart | Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ), Head &Amp; Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC) | 61 | 2026-02-23 | Dec 2027 | ≤ 498 d | 2026-03-27 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical CancerNCT04697628results2024-08-09Overall Survival | Phase 3 | Completed | Drug: tisotumab vedotin, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed | Cervical Cancer | 502 | 2021-02-22 | 2023-07-24actual | — | 2026-02-24 |
| ABBV | AbbVie | $457.5B | First in Human Study of IMGN151 in Recurrent Gynaecological CancersNCT05527184Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Active, not recruiting | Drug: IMGN151 | Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cervical Cancer | 256 | 2023-01-11 | Feb 2027 | ≤ 192 d | 2026-02-20 |
| TNG.PA | Transgene | $231M | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M CancersNCT03260023results2025-12-02Phase Ib: To Evaluate the Safety and Tolerability of the Combination of TG4001 Plus Avelumab in Participants With Recurrent or Metastatic HPV-16 Positive Advanced Malignancies | Phase 1/2 | Active, not recruiting | Biological: TG4001 · Drug: Avelumab | HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma | 143 | 2017-09-01 | 2024-09-18actual | — | 2026-02-05 |
| IBRX | ImmunityBio, Inc. | $8.2B | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsNCT03228667ORR, defined as Investigator-assessed CR + PR per RECIST v1.1. | Phase 2 | Active, not recruiting | Drug: N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab | Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer | 40 | 2018-12-11 | 2029-08-31 | in 1,107 d | 2026-01-14 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsNCT04579380results2024-11-13Confirmed Objective Response Rate (cORR) as Assessed by Investigator | Phase 2 | Active, not recruiting | Drug: tucatinib, trastuzumab, fulvestrant | Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms | 217 | 2021-01-11 | 2023-11-01actual | — | 2025-12-19 |
| CRSP | CRISPR Therapeutics AG | $5.1B | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid TumorsNCT05795595Phase 1 (Dose Escalation): Incidence of adverse events | Phase 1/2 | Completed | Biological: CTX131 | Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma, Malignant Pleural Mesothelioma | 19 | 2023-03-13 | 2025-09-18actual | — | 2025-11-26 |
| TCRX | TScan Therapeutics, Inc. | $107M | A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid TumorsNCT05812027observationalFrequency of subjects with TAA expression, HLA typing and HLA loss. | — | Active, not recruiting | Diagnostic test: Tumor and HLA Profiling | Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers, Sarcoma, Uveal Melanoma, NUT Carcinoma | 1,150 | 2023-06-26 | 2026-01-01 | — | 2025-11-17 |
| TCRX | TScan Therapeutics, Inc. | $107M | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid TumorsNCT05973487Evaluate the safety of monotherapy and T- Plex combination TCR-Ts | Phase 1 | Active, not recruiting | Biological: TSC-204-A0201, TSC-204-C0702, TSC-200-A0201, TSC-204-A0201 + TSC-204-C0702, TSC-204-A0201 + TSC-200-A0201, TSC-204-C0702 + TSC-200-A0201, TSC-204-A0201 + TSC-203-A0201, TSC-204-C0702 + TSC-203-A0201, TSC-200-A0201 + TSC-203-A0201, TSC-203-A0201, TSC-204-A0101, TSC-201-B0702, TSC-204-A0201 + TSC-204-A0101, TSC-204-A0201 + TSC-201-B0702, TSC-204-C0702 + TSC-204-A0101, TSC-204-C0702 + TSC-201-B0702, TSC-200-A0201 + TSC-204-A0101, TSC-200-A0201 + TSC-201-B0702, TSC-203-A0201 + TSC-204-A0101, TSC-203-A0201 + TSC-201-B0702, TSC-202-A0201, TSC-204-A0201 + TSC-202-A0201, TSC-204-C0702 + TSC-202-A0201, TSC-200-A0201 + TSC-202-A0201, TSC-203-A0201 + TSC-202-A0201, TSC-204-A0101 + TSC-202-A0201, TSC-201-B0702 + TSC-202-A0201 | Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma, Ovarian Cancer, Anogenital Cancers, HPV - Anogenital Human Papilloma Virus Infection, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Malignancy, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma | 840 | 2024-05-06 | 2026-12-30 | in 132 d | 2025-11-17 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study to Investigate the Prevalence of Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ and Characterize the Clinicopathologic Features of Gynecologic Cancers in TaiwanNCT06925113observationalTo understand the prevalence rate of HER2 IHC 3+ in recurrent advanced endometrial cancer, ovarian cancer, and cervical cancer in Taiwan | — | Completed | — | Cervical Cancers, Endometrial Cancer, Ovarian Cancer | 509 | 2025-01-31 | 2025-08-31actual | — | 2025-11-17 |
| INCY | Incyte Corporation | $24.7B | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid TumorsNCT04272034Number of treatment-emergent adverse events | Phase 1 | Terminatedsponsor's stated reason: A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision. | Drug: INCB099318 | Advanced Solid Tumors, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, HCC, Cervical Cancer, Esophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma, PD-L1 Amplified Tumor (9p24.1), Nasopharyngeal Carcinoma, Cyclin-dependent Kinase 12 Mutated Tumors, Basal Cell Carcinoma (Unresectable or Metastatic), Sarcomatoid Renal Cell Carcinoma, Clear Cell Ovarian or Endometrial Carcinoma, Anal Carcinoma, Squamous Cell Penile Carcinoma, DNA Polymerase Epsilon Mutated Tumors (P286R and V411L) | 105 | 2021-03-26 | 2024-08-16actual | — | 2025-10-16 |
| NRIX | Nurix Therapeutics, Inc. | $2.8B | A Study of NX-1607 in Adults With Advanced MalignanciesNCT05107674Incidence of treatment-emergent adverse events (TEAEs), including Grade ≥ 3 TEAEs, treatment-emergent serious adverse events (SAEs), TEAEs leading to study drug discontinuation, and deaths due to TEAEs | Phase 1 | Recruiting | Drug: NX-1607, Paclitaxel | Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma | 345 | 2021-09-29 | 2026-08-31 | in 11 d | 2025-09-09 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line ChemotherapyNCT04646005results2024-09-19Objective Response Rate (ORR) | Phase 2 | Completed | Drug: Cemiplimab · Biological: ISA101b | Cervical Cancer | 113 | 2021-06-28 | 2023-05-22actual | — | 2025-09-08 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced MalignanciesNCT04772989Percentage of participants with Adverse Events | Phase 1 | Completed | Drug: AB308, Zimberelimab | Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer, Multiple Myeloma, Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma (DLBCL), Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer | 94 | 2021-03-19 | 2025-08-25actual | — | 2025-08-28 |
| AGEN | Agenus Inc. | $339M | A Study of AGEN2034 in Advanced Tumors and Cervical CancerNCT03104699results2025-07-30Phase 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) for Balstilimab | Phase 1/2 | Completed | Drug: AGEN2034 | Advanced Cancer, Cervical Cancer | 211 | 2017-04-11 | 2022-06-15actual | — | 2025-07-30 |
| INCY | Incyte Corporation | $24.7B | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid TumorsNCT04242199Number of treatment-emergent adverse events | Phase 1 | Completed | Drug: INCB099280 | Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, HepatoCellular Carcinoma, Esophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma, PD-L1 Amplified Tumor (9p24.1), Nasopharyngeal Carcinoma | 182 | 2020-09-04 | 2024-08-29actual | — | 2025-07-14 |
| MDNAF | Medicenna Therapeutics, Inc. | $22M | A Beta-only IL-2 ImmunoTherapY StudyNCT05086692MDNA11 Recommended Dose for Expansion for monotherapy (mRDE) and Recommended Dose for Expansion for combination (cRDE) | Phase 1/2 | Recruiting | Drug: MDNA11, Pembrolizumab (KEYTRUDA®) | Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer | 115 | 2021-08-27 | 2026-06-30 | — | 2025-07-09 |
| BDX | Becton, Dickinson and Company | $49.2B | Clinical Trial for Registration of HPV Nucleic Acid Genotyping Assay KitNCT04461678Verification of the accuracy of nucleic acid assay | Not applicable | Completed | Diagnostic test: HPV Genotyping Nucleic Acid Assay Kit | Cervical Cancer | 12,230 | 2020-08-23 | 2024-08-26actual | — | 2025-07-02 |
| AZN | AstraZeneca | — | Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment SchedulesNCT01226316Parts A,B,C,D,E & F : Safety and tolerability of AZD5363 in terms of adverse events and serious adverse events | Phase 1 | Completed | Drug: AZD5363, AZD5363, AZD5363, AZD5363 | Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, Tumour Response, Advanced or Metastatic Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, PIK3CA, AKT1, PTEN, ER Positive, HER2 Positive | 285 | 2010-12-01 | 2019-04-26actual | — | 2025-06-29 |
| EXEL | Exelixis | $13.2B | Study of XB002 in Subjects With Solid Tumors (JEWEL-101)NCT04925284Dose-Escalation Stage: MTD/recommended dose for XB002 | Phase 1 | Completed | Drug: XB002, Nivolumab, Bevacizumab | Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors | 269 | 2021-06-07 | 2025-03-10actual | — | 2025-04-04 |
| PFE | Pfizer | $155.3B | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various CancerNCT04889495observationalSafety profile | — | Withdrawnsponsor's stated reason: The study was withdrawn due to global supply chain issue. Zirabev was not launching in Korea. | Drug: Zirabev | Non-small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Metastatic Kidney Cancer, Cervical Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 0 | 2025-05-16 | 2025-08-16 | — | 2025-03-19 |
| XNCR | Xencor, Inc. | $1.9B | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary MalignanciesNCT05032040PSA50 is the primary endpoint for the mCRPC cohort. Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumours (RECIST) version 1 criteria is the primary endpoint for gynecological malignancy cohorts | Phase 2 | Active, not recruiting | Biological: vudalimab | Ovarian Cancer, Clear Cell Carcinoma, Endometrial Cancer, Cervical Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 170 | 2022-07-21 | 2025-10-15 | — | 2025-02-07 |
| AZN | AstraZeneca | — | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid TumoursNCT04504669Maximum Tolerated dose (or optimal dose or maximum feasible dose) and RP2D of AZD8701 as monotherapy and in combination with Durvalumab assessed through evaluation of AEs and SAEs | Phase 1 | Completed | Drug: AZD8701 · Biological: Durvalumab | Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck, Small Cell Lung Cancer, Gastroesophageal Cancer, Melanoma, Cervical Cancer, Advanced Solid Tumours | 60 | 2020-08-18 | 2024-10-07actual | — | 2024-11-05 |
| AZN | AstraZeneca | — | Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)NCT03830866results2023-03-06Progression-free Survival (PFS) Based on the Investigator Assessment According to RECIST 1.1 or Histopathologic Confirmation of Local Tumour Progression | Phase 3 | Completed | Biological: Durvalumab · Drug: Cisplatin, Carboplatin · Radiation: external beam radiation therapy (EBRT) + brachytherapy | Locally Advanced Cervical Cancer | 770 | 2019-02-15 | 2022-01-20actual | — | 2024-07-26 |
| XNCR | Xencor, Inc. | $1.9B | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)NCT03752398Treatment-related adverse events as assessed by CTCAE v4.03 | Phase 1 | Completed | Biological: XmAb®23104, Yervoy® (ipilimumab) | Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma | 198 | 2019-05-01 | 2024-02-15actual | — | 2024-07-05 |
| NRIX | Nurix Therapeutics, Inc. | $2.8B | A Study of DeTIL-0255 in Adults With Advanced MalignanciesNCT05107739Incidence of treatment emergent adverse events | Phase 1 | Terminatedsponsor's stated reason: Sponsor Decision | Biological: Drug Product De-TIL-0255 | Platinum-resistant Ovarian Cancer, Endometrial Cancer, Cervical Cancer | 5 | 2021-12-22 | 2023-05-09actual | — | 2024-05-03 |
| AGEN | Agenus Inc. | $339M | A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical CancerNCT05033132Objective Response Rate (ORR) Of Balstilimab Monotherapy Per Independent Review Committee (IRC) Assessment Based Upon Response Evaluation Criteria In Solid Tumours (RECIST) 1.1 | Phase 2 | Withdrawnsponsor's stated reason: Study was never initiated. | Drug: Balstilimab, Balstilimab + Zalifrelimab | Cervical Cancer | 0 | 2021-10-01 | 2024-12-30 | — | 2024-03-28 |
| MGNX | MacroGenics | $261M | A Study of MGD013 in Patients With Unresectable or Metastatic NeoplasmsNCT03219268Number of participants with Treatment-Emergent Adverse Events (TEAE) as assessed by CTCAE v4.03 (tebotelimab monotherapy) | Phase 1 | Completed | Biological: tebotelimab 1 mg, tebotelimab 3 mg, tebotelimab 10 mg, tebotelimab 30 mg, tebotelimab 120 mg, tebotelimab 300 mg, tebotelimab 400 mg, tebotelimab 600 mg, tebotelimab 800 mg, tebotelimab 1200 mg, margetuximab | Advanced Solid Tumors, Hematologic Neoplasms, Ovarian Cancer, HER2-positive Advanced Solid Tumors, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Cervical Cancer, TNBC - Triple-Negative Breast Cancer | 277 | 2017-08-18 | 2023-02-08actual | — | 2023-12-21 |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.2B | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced CancersNCT03454451Incidence of dose-limiting toxicities (DLTs) of CPI-006 as a single agent and in combination with ciforadenant and with pembrolizumab. | Phase 1 | Completed | Drug: CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab, CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab | Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Cervical Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Metastatic Castration Resistant Prostate Cancer, Non-hodgkin Lymphoma | 117 | 2018-04-25 | 2022-12-28actual | — | 2023-12-21 |
| FATE | Fate Therapeutics | $307M | Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular ImmunotherapyNCT04106167observationalOverall Survival (OS) post-Infusion | — | Terminatedsponsor's stated reason: This study was terminated by the Sponsor. | Genetic: Allogeneic natural killer (NK) cell | Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma | 20 | 2019-06-11 | 2023-08-11actual | — | 2023-09-21 |
| BDX | Becton, Dickinson and Company | $49.2B | Intended Use Study of the BD SurePath Plus™ PapNCT01234480results2021-05-05Sensitivity, Specificity, PPV, and NPV of BD SurePath Plus Pap Test for the Determination of Cervical Disease as Defined by CIN2 or Higher | — | Terminatedsponsor's stated reason: Decided not to pursue commercialization of the product | Device: BD SurePath Plus Pap test, BD SurePath Pap test, HPV DNA test · Procedure: colposcopy with biopsy/ECC | Uterine Cervical Neoplasms, Uterine Cervical Cancer, Neoplasms, Squamous Cell, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Neoplasms, Papilloma | 5,859 | Sep 2010 | Mar 2012actual | — | 2023-05-16 |
| FATE | Fate Therapeutics | $307M | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsNCT03841110The incidence of participants with Dose Limiting Toxicities (DLTs) within each dose level cohort. | Phase 1 | Completed | Drug: FT500, Nivolumab, Pembrolizumab, Atezolizumab, Cyclophosphamide, Fludarabine, IL-2 | Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma | 37 | 2019-02-15 | 2022-11-15actual | — | 2023-05-01 |
| XNCR | Xencor, Inc. | $1.9B | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsNCT03849469Safety and tolerability profile of XmAb22841 assessed by rates of treatment-related adverse events (AEs), graded by CTCAE v4.03. | Phase 1 | Completed | Biological: XmAb®22841, Pembrolizumab (Keytruda®) | Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma | 78 | 2019-05-29 | 2023-02-16actual | — | 2023-03-30 |
| PRLD | Prelude Therapeutics | $459M | A Study of PRT1419 in Patients With Advanced Solid TumorsNCT04837677Dose limiting toxicities (DLT) of PRT1419 | Phase 1 | Completed | Drug: PRT1419 | Sarcoma, Melanoma, Lung Cancer, Breast Cancer, Esophageal Cancer, Cervical Cancer, Head and Neck Cancer | 26 | 2021-08-11 | 2023-02-06actual | — | 2023-03-15 |
| KPTI | Karyopharm Therapeutics Inc | $44M | Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic MalignanciesNCT02025985results2021-02-02Percentage of Participants With Disease Control Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Phase 2 | Completed | Drug: Selinexor | Ovarian Carcinoma, Endometrial Carcinoma, Cervical Carcinoma | 116 | 2014-04-09 | 2017-01-24actual | — | 2023-01-26 |
| TIL | Instil Bio | $50M | ITIL-168 in Advanced Solid TumorsNCT05393635Frequency and severity of ITIL-168 treatment-emergent adverse events (AEs), serious AEs, and AEs of special interest | Phase 1 | Withdrawnsponsor's stated reason: business decision | Biological: ITIL-168 | Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer | 0 | Aug 2022 | 2022-12-08actual | — | 2022-12-20 |
| XNCR | Xencor, Inc. | $1.9B | A Study of XmAb®20717 in Subjects With Selected Advanced Solid TumorsNCT03517488Determine the safety and tolerability profile of XmAb20717 | Phase 1 | Completed | Biological: XmAb20717 | Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Non-small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Mesothelioma, Neuroendocrine Carcinoma, Cervical Cancer, Small Cell Lung Carcinoma, Squamous Cell Carcinoma of the Anus, Castration-Resistant Prostate Carcinoma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Basal Cell Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Thymoma, Thymic Carcinoma, Squamous Cell Carcinoma of the Penis, Vulvar Carcinoma, Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy, Malignant Adnexal Neoplasms, Non-squamous Cell Salivary Gland Carcinoma | 150 | 2018-07-10 | 2022-06-01actual | — | 2022-12-01 |
| AGEN | Agenus Inc. | $339M | Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)NCT04943627Overall survival in patients with PD-L1 positive tumors randomized to BAL vs Investigator's Choice chemotherapy | Phase 3 | Withdrawnsponsor's stated reason: Strategic Business Decision | Drug: Balstilimab (BAL), Topotecan, Vinorelbine, Gemcitabine, Irinotecan, Pemetrexed | Advanced Cancer, Metastatic Cervical Cancer | 0 | 2021-08-02 | 2021-10-22actual | — | 2022-10-05 |
| INCY | Incyte Corporation | $24.7B | A Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesNCT03652077Number of treatment-emergent adverse events | Phase 1 | Completed | Drug: INCAGN02390 | Cervical Cancer, Gastric Cancer, Stomach Cancer, Gastroesophageal Junction Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Melanoma, Uveal Melanoma, Merkel Cell Carcinoma, Mesothelioma, MSI, Non-small Cell Lung Cancer, NSCLC, Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck, Small Cell Lung Cancer, Renal Cell Carcinoma, RCC, Triple-negative Breast Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency | 40 | 2018-09-24 | 2021-08-18actual | — | 2021-11-15 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3435151 in Participants With Solid TumorsNCT04099277results2021-08-31Number of Participants With LY3435151 Dose-Limiting Toxicities (DLTs) | Phase 1 | Terminatedsponsor's stated reason: Study terminated due to strategic business decision by Eli Lilly and Company. | Drug: LY3435151, Pembrolizumab | Solid Tumor, Triple-negative Breast Cancer, Gastric Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Cervical Carcinoma, High Grade Serous Ovarian Carcinoma, Hepatocellular Carcinoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma | 2 | 2019-10-28 | 2020-03-05actual | — | 2021-08-31 |
| GILD | Gilead Sciences | $177.9B | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerNCT01631552results2021-04-06Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events | Phase 1/2 | Completed | Drug: Sacituzumab Govitecan-hziy (SG) | Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Head and Neck Cancers- Squamous Cell, Renal Cell Cancer, Urinary Bladder Neoplasms, Cervical Cancer, Endometrial Cancer, Glioblastoma Multiforme, Triple Negative Breast Cancer, Pancreatic Cancer | 515 | 2012-12-17 | 2019-03-01actual | — | 2021-08-12 |
| PBYI | Puma Biotechnology, Inc. | $477M | HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of NeratinibNCT03786107observationalNumber of Participants Eligible for Neratinib Treatment | — | Terminatedsponsor's stated reason: The study was stopped early due to increased global access to genomic screening. It is no longer economical to continue with this particular single-gene screening protocol. | Diagnostic test: Almac HER-Seq Assay | Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer, Metastatic Cervical Cancer | 1,583 | 2019-03-14 | 2021-01-21actual | — | 2021-05-19 |
| INO | Inovio Pharmaceuticals | $124M | A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical CancerNCT02172911results2021-02-21Percentage of Participants With at Least 1 Treatment Emergent Adverse Event (TEAE) | Phase 1/2 | Completed | Biological: INO-3112 · Device: CELLECTRA™-5P | Cervical Cancer | 10 | 2014-06-06 | 2017-09-07actual | — | 2021-02-21 |
| 4568.T | Daiichi Sankyo Co., Ltd. | $31.7B | An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid TumorsNCT01040312observationalNumber of Participants with UGT1A1 Genotype with Severe Toxicities Induced by CPT-11 with Platinum Analogues | — | Completed | Drug: CPT-11, Platinum analogues | Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Ovarian Cancer, Gastric Cancer (Inoperable and Recurrent) | 321 | 2009-10-15 | 2014-09-29actual | — | 2019-05-23 |
| INO | Inovio Pharmaceuticals | $124M | A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3NCT01304524Number of Participants with Histopathological Regression of Cervical Lesions to CIN 1 or Less as a Measure of Efficacy. | Phase 2 | Completed | Biological: VGX 3100, Placebo · Device: CELLECTRA™-5P | Cervical Intraepithelial Neoplasia | 167 | Apr 2011 | May 2014actual | — | 2018-09-07 |
| BDX | Becton, Dickinson and Company | $49.2B | Clinical Evaluation of the BD Onclarity™ HPV Assay on the BD Viper™ LT System With Cervical SpecimensNCT01944722results2018-04-18Sensitivity of the BD Onclarity™ HPV Assay for the Detection Cervical Disease as Defined by Cervical Intraepithelial Neoplasia (CIN)2 or Greater | Not applicable | Completed | Device: BD Onclarity™ HPV assay on BD Viper™ LT · Procedure: Colposcopy | Uterine Cervical Neoplasms | 33,858 | Aug 2013 | Mar 2016actual | — | 2018-06-12 |
| TRAW | Traws Pharma, Inc. | $8M | Oral Rigosertib for Squamous Cell CarcinomaNCT01807546Overall response rate | Phase 2 | Completed | Drug: rigosertib | Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Skin Squamous Cell Carcinoma, Penile Squamous Cell Carcinoma | 64 | Mar 2013 | Mar 2015actual | — | 2017-06-26 |
| PHO.OL | Photocure | — | Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical NeoplasiaNCT01256424results2014-08-21Comparison of Lesion Response Rates of Three Different Doses of HAL PDT and Placebo at 3 Months After Treatment. | Phase 2 | Completed | Drug: HAL 5% with illumination, HAL 1% with illumination, HAL 0.2% with illumination, Placebo ointment without illumination | Cervical Intraepithelial Neoplasia | 262 | Apr 2011 | Sep 2012actual | — | 2016-05-16 |
| PFE | Pfizer | $155.3B | Irinotecan Study For Cervical CancerNCT00136955results2009-06-25Response to Treatment Based on Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (Evaluable Population) | Phase 2 | Completed | Drug: Irinotecan | Uterine Cervical Neoplasms | 41 | Jun 2004 | May 2008actual | — | 2015-06-19 |
| BDX | Becton, Dickinson and Company | $49.2B | European Clinical Evaluation of the BD HPV Assay on the BD Viper LT SystemNCT01671462observationalSensitivity of the BD HPV Assay with 95% confidence intervals for detecting cervical disease as defined by Cervical Intraepithelial Neoplasia (CIN2) or higher. | — | Completed | Device: BD HPV assay on Viper LT | Uterine Cervical Neoplasms | 1,365 | Aug 2012 | Nov 2013actual | — | 2014-02-20 |
| PHO.OL | Photocure | — | Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1NCT00708942results2013-04-15Complete Response Rate | Phase 2 | Terminatedsponsor's stated reason: Slow recruitment, study stopped with only 13 of 70 patients included in second part of the study | Drug: Hexaminolevulinate (HAL), Placebo, Hexaminolevulinate (HAL), Placebo | Cervical Intraepithelial Neoplasia | 83 | Jan 2009 | Jan 2012actual | — | 2013-04-24 |
| 4568.T | Daiichi Sankyo | $31.7B | DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the CervixNCT00004866 | Phase 2 | Completed | Drug: exatecan mesylate | Cervical Cancer | — | Jan 2000 | Sep 2003actual | — | 2012-05-16 |
| MNKD | Mannkind Corporation | $1.3B | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.NCT00423254To determine the immunologic response to the treatment with MKC1106-PP regimen and 2) to determine the safety and adverse event profile of MKC1106-PP | Phase 1 | Completed | Biological: PSMA/PRAME, PSMA/PRAME | Ovarian, Melanoma, Renal, Prostate, Colorectal, Endometrial Carcinoma, Cervical Carcinoma, Testicular Cancer, Thyroid Cancer, Small Cell Lung Carcinoma, Mesothelioma, Breast Carcinoma, Esophageal Carcinoma, Gastric Cancer, Pancreatic Carcinoma, Neuroendocrine Cancer, Liver Cancer, Gallbladder Cancer, Biliary Tract Cancer, Anal Carcinoma, Bone Sarcomas, Soft Tissue Sarcomas, Carcinoma of Unknown Origin, Primary | 12 | Feb 2007 | Sep 2009actual | — | 2010-08-03 |
| LLY | Eli Lilly and Company | $1.15T | A Trial for Patients With Advanced/Recurrent Cervical CancerNCT00190983results2009-08-24Tumor Response | Phase 2 | Completed | Drug: Pemetrexed | Cervical Intraepithelial Neoplasia, Uterine Neoplasms, Genital Neoplasms, Female | 29 | Feb 2005 | Oct 2007actual | — | 2009-11-20 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Cervical Cancer is matched — 9 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Cervical Cancer
- Cervical Carcinoma
- Uterine Cervical Neoplasms
- Cervical Intraepithelial Neoplasia
- Locally Advanced Cervical Cancer
- Metastatic Cervical Cancer
- Cervical Cancers
- Cervical Squamous Cell Carcinoma
- HPV-Related Cervical Carcinoma
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Cervical Cancer” (a text search, wider than this page)